Comparing the current results to its competitors, Oragenics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 1.72 %, recorded in the same quarter.
Oragenics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive landscape that includes numerous nutraceutical, pharmaceutical, biopharmaceutical, medical device, and biotechnology firms. Key competitors include Merck & Co., Inc., GlaxoSmithKline plc, CSL Ltd., Sanofi Pasteur, SA, Pfizer Inc., Johnson & Johnson, AstraZeneca, and Moderna. These competitors are often large, well-established companies with extensive research, development, financial, scientific, marketing, and human resources capabilities. They possess greater experience in securing government contracts and grants, conducting testing and clinical trials, obtaining regulatory approvals, manufacturing at scale, and marketing approved products. Consequently, these companies may develop competing products earlier, secure blocking patents, achieve faster regulatory approvals, create safer or more effective treatments, allocate more resources to marketing, and better withstand price competition.
August 16, 2024
Sarasota, Fla. - August 16, 2024 Oragenics, Inc. (NYSE American: OGEN), a pioneering biopharmaceutical company focused on developing innovative intranasal treatments for neurological disorders, has provided notable updates on its progress towards the advancement of its investigational drug, ONP-002. The company aims to establish a viable treatment for concussions, with plans for Phase II human trials expected to commence in the fourth quarter of 2024.In a recent press release, Oragenics articulated its commitment to executing its business strategy, emphasizing ongoing efforts towards the clinical advancement of ONP-002, an innovative neurosteroid specifically designed for the treatment of mild Traumatic B...
May 7, 2024
Sophisticated Oragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaSARASOTA, Fla., May 07, 2024 - Oragenics, Inc. (NYSE American: OGEN), a pioneering company in the development of innovative intranasal pharmaceuticals for neurological disorders, has recently announced an exciting partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. The primary of this trial is to evaluate the efficacy and safety of Oragenics lead drug candidate, ONP-002, for the treatment of mild Traumatic Brain Injury (TBI), commonly known as concussion. ONP-002, categorized as a novel chemical entity (NCE), will be administered th...
Fortress Biotech Inc operates as a biopharmaceutical company that acquires, develops, and commercializes novel pharmaceutical and biotechnology products. Their business model focuses on partnering with academic institutions and biotech companies to advance preclinical and clinical-stage therapies for various diseases. Additionally, they aim to leverage their expertise and partnerships to improve the development process and bring innovative treatments to patients in need.
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Sources:
Oragenics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oragenics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
